Designed for Multi-Cancer Early Detection (MCED) tests for over 40 cancers, the latest prototype of the Cube™ will also aim to detect infectious diseases using a single, 5ml sample of blood or urine.

The Cube is a desktop lab device designed to precisely extract volatile organic compounds (VOCs) from any liquid sample (e.g. blood or urine) as two on-board NanoBiosensors rapidly examine the VOCs for multiple diseases. 

The current design allows for up to 18 samples to be loaded at a time using a tray approach that will easily allow for full automation in the future. We believe the Cube’s potential for high-throughput, early detection could dramatically impact diagnostic availability and lower the overall cost of the healthcare.